Cayman
Showing 26401–26550 of 45550 results
-
KJ Pyr 9 is a cell-permeable inhibitor of c-Myc (Kd = 6.5 nM) that interferes with Myc-Max complex formation in cells.{31163,31164} It preferentially blocks the proliferation of c-Myc-overexpressing cells, reducing Myc-driven gene expression.{31163} KJ Pyr 9 also potently blocks cell growth directed by overexpression of v-Myc, while less effectively blocking N-Myc- and L-Myc-dependent proliferation.{31164} It is effective in vivo, reducing the growth of breast cancer MDA-MB-231 xenografts in mice.{31163}
Brand:CaymanSKU:-Available on backorder
KJ Pyr 9 is a cell-permeable inhibitor of c-Myc (Kd = 6.5 nM) that interferes with Myc-Max complex formation in cells.{31163,31164} It preferentially blocks the proliferation of c-Myc-overexpressing cells, reducing Myc-driven gene expression.{31163} KJ Pyr 9 also potently blocks cell growth directed by overexpression of v-Myc, while less effectively blocking N-Myc- and L-Myc-dependent proliferation.{31164} It is effective in vivo, reducing the growth of breast cancer MDA-MB-231 xenografts in mice.{31163}
Brand:CaymanSKU:-Available on backorder
KJ Pyr 9 is a cell-permeable inhibitor of c-Myc (Kd = 6.5 nM) that interferes with Myc-Max complex formation in cells.{31163,31164} It preferentially blocks the proliferation of c-Myc-overexpressing cells, reducing Myc-driven gene expression.{31163} KJ Pyr 9 also potently blocks cell growth directed by overexpression of v-Myc, while less effectively blocking N-Myc- and L-Myc-dependent proliferation.{31164} It is effective in vivo, reducing the growth of breast cancer MDA-MB-231 xenografts in mice.{31163}
Brand:CaymanSKU:-Available on backorder
The cryptochrome proteins CRY1 and CRY2, which play central roles in maintaining the circadian clock, are expressed and then degraded in a rhythmic pattern.{14833,21468} KL001 is a cell-permeable carbazolic compound which directly interacts with and stabilizes CRY1 and CRY2, preventing ubiquitin-dependent degradation while lengthening the circadian period (IC50 = 0.82-14 μM).{21468} As the expression of some gluconeogenic genes is both circadian and cryptochrome-dependent, KL001 effectively inhibits glucagon-induced gluconeogenesis in primary hepatocytes.{21468} This product can be used to study the regulation of cryptochrome-dependent physiology and aid in the development of clock-based therapeutics of diabetes.
Brand:CaymanSKU:- The cryptochrome proteins CRY1 and CRY2, which play central roles in maintaining the circadian clock, are expressed and then degraded in a rhythmic pattern.{14833,21468} KL001 is a cell-permeable carbazolic compound which directly interacts with and stabilizes CRY1 and CRY2, preventing ubiquitin-dependent degradation while lengthening the circadian period (IC50 = 0.82-14 μM).{21468} As the expression of some gluconeogenic genes is both circadian and cryptochrome-dependent, KL001 effectively inhibits glucagon-induced gluconeogenesis in primary hepatocytes.{21468} This product can be used to study the regulation of cryptochrome-dependent physiology and aid in the development of clock-based therapeutics of diabetes.
Brand:CaymanSKU:- The cryptochrome proteins CRY1 and CRY2, which play central roles in maintaining the circadian clock, are expressed and then degraded in a rhythmic pattern.{14833,21468} KL001 is a cell-permeable carbazolic compound which directly interacts with and stabilizes CRY1 and CRY2, preventing ubiquitin-dependent degradation while lengthening the circadian period (IC50 = 0.82-14 μM).{21468} As the expression of some gluconeogenic genes is both circadian and cryptochrome-dependent, KL001 effectively inhibits glucagon-induced gluconeogenesis in primary hepatocytes.{21468} This product can be used to study the regulation of cryptochrome-dependent physiology and aid in the development of clock-based therapeutics of diabetes.
Brand:CaymanSKU:-
The rabbit anti-KLH polyclonal antibody is intended for use as a negative control rabbit antibody for use with experiments utilizing a primary antibody from rabbit. It may also be used to detect KLH from biological samples. This antibody has a detection limit for KLH to the low nanogram level but little or no cross reactivity to protein samples (cell or tissue lysates) derived from mammals.
Brand:CaymanSKU:14046 - 1 eaAvailable on backorder
Brand:CaymanSKU:14046- 1 eaAvailable on backorder
Brand:CaymanSKU:14046- 1 ea
KLH45 is an inhibitor of the phospholipase DDHD domain containing 2 (DDHD2; IC50 = 1.3 nM).{43899} It is selective for DDHD2 over greater than 50 serine hydrolases, including DDHD1 and Sec23ip, but does inhibit α/β-hydrolase domain-containing protein 6 (ABHD6). It inhibits DDHD2 and ABHD6 in Neuro2A cells when used at a concentration of less than 10 nM and inhibits DDHD2 by greater than 95% at a concentration of 25 nM. KLH45 (2 µM) prevents increases in triacylglycerol (TAG) hydrolase activity in HEK293T cell lysates expressing recombinant DDHD2 and incubated with a radiolabeled TAG substrate. It decreases TAG levels in the CNS of mice when administered at a dose of 20 mg/kg twice per day for four days. KLH45 (2 µM) also reverses DDHD2-induced lipid droplet reduction in COS-7 cells expressing recombinant DDHD2 and loaded with oleic acid.{43900}
Brand:CaymanSKU:19889 -Available on backorder
KLH45 is an inhibitor of the phospholipase DDHD domain containing 2 (DDHD2; IC50 = 1.3 nM).{43899} It is selective for DDHD2 over greater than 50 serine hydrolases, including DDHD1 and Sec23ip, but does inhibit α/β-hydrolase domain-containing protein 6 (ABHD6). It inhibits DDHD2 and ABHD6 in Neuro2A cells when used at a concentration of less than 10 nM and inhibits DDHD2 by greater than 95% at a concentration of 25 nM. KLH45 (2 µM) prevents increases in triacylglycerol (TAG) hydrolase activity in HEK293T cell lysates expressing recombinant DDHD2 and incubated with a radiolabeled TAG substrate. It decreases TAG levels in the CNS of mice when administered at a dose of 20 mg/kg twice per day for four days. KLH45 (2 µM) also reverses DDHD2-induced lipid droplet reduction in COS-7 cells expressing recombinant DDHD2 and loaded with oleic acid.{43900}
Brand:CaymanSKU:19889 -Available on backorder
KLH45 is an inhibitor of the phospholipase DDHD domain containing 2 (DDHD2; IC50 = 1.3 nM).{43899} It is selective for DDHD2 over greater than 50 serine hydrolases, including DDHD1 and Sec23ip, but does inhibit α/β-hydrolase domain-containing protein 6 (ABHD6). It inhibits DDHD2 and ABHD6 in Neuro2A cells when used at a concentration of less than 10 nM and inhibits DDHD2 by greater than 95% at a concentration of 25 nM. KLH45 (2 µM) prevents increases in triacylglycerol (TAG) hydrolase activity in HEK293T cell lysates expressing recombinant DDHD2 and incubated with a radiolabeled TAG substrate. It decreases TAG levels in the CNS of mice when administered at a dose of 20 mg/kg twice per day for four days. KLH45 (2 µM) also reverses DDHD2-induced lipid droplet reduction in COS-7 cells expressing recombinant DDHD2 and loaded with oleic acid.{43900}
Brand:CaymanSKU:19889 -Available on backorder
KLH45 is an inhibitor of the phospholipase DDHD domain containing 2 (DDHD2; IC50 = 1.3 nM).{43899} It is selective for DDHD2 over greater than 50 serine hydrolases, including DDHD1 and Sec23ip, but does inhibit α/β-hydrolase domain-containing protein 6 (ABHD6). It inhibits DDHD2 and ABHD6 in Neuro2A cells when used at a concentration of less than 10 nM and inhibits DDHD2 by greater than 95% at a concentration of 25 nM. KLH45 (2 µM) prevents increases in triacylglycerol (TAG) hydrolase activity in HEK293T cell lysates expressing recombinant DDHD2 and incubated with a radiolabeled TAG substrate. It decreases TAG levels in the CNS of mice when administered at a dose of 20 mg/kg twice per day for four days. KLH45 (2 µM) also reverses DDHD2-induced lipid droplet reduction in COS-7 cells expressing recombinant DDHD2 and loaded with oleic acid.{43900}
Brand:CaymanSKU:19889 -Available on backorder
KM 11060 is a small molecule that corrects the processing of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation carried by 90% of cystic fibrosis patients.{36264} It increases cell surface expression and restores chloride transport function of F508del-CFTRs in BHK cells at a concentration of 10 μM. KM 11060 restores F508del-CFTR function, as measured by cAMP-stimulated iodide efflux, in CFBE41o- human airway epithelial cells at a concentration of 10 nM. It also restores the secretory response to approximately 51% of wild-type levels ex vivo in ileum isolated from F508del-CFTR mice at a concentration of 20 μM.
Brand:CaymanSKU:23481 - 10 mgAvailable on backorder
KM 11060 is a small molecule that corrects the processing of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation carried by 90% of cystic fibrosis patients.{36264} It increases cell surface expression and restores chloride transport function of F508del-CFTRs in BHK cells at a concentration of 10 μM. KM 11060 restores F508del-CFTR function, as measured by cAMP-stimulated iodide efflux, in CFBE41o- human airway epithelial cells at a concentration of 10 nM. It also restores the secretory response to approximately 51% of wild-type levels ex vivo in ileum isolated from F508del-CFTR mice at a concentration of 20 μM.
Brand:CaymanSKU:23481 - 25 mgAvailable on backorder
KM 11060 is a small molecule that corrects the processing of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation carried by 90% of cystic fibrosis patients.{36264} It increases cell surface expression and restores chloride transport function of F508del-CFTRs in BHK cells at a concentration of 10 μM. KM 11060 restores F508del-CFTR function, as measured by cAMP-stimulated iodide efflux, in CFBE41o- human airway epithelial cells at a concentration of 10 nM. It also restores the secretory response to approximately 51% of wild-type levels ex vivo in ileum isolated from F508del-CFTR mice at a concentration of 20 μM.
Brand:CaymanSKU:23481 - 5 mgAvailable on backorder
KM 11060 is a small molecule that corrects the processing of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation carried by 90% of cystic fibrosis patients.{36264} It increases cell surface expression and restores chloride transport function of F508del-CFTRs in BHK cells at a concentration of 10 μM. KM 11060 restores F508del-CFTR function, as measured by cAMP-stimulated iodide efflux, in CFBE41o- human airway epithelial cells at a concentration of 10 nM. It also restores the secretory response to approximately 51% of wild-type levels ex vivo in ileum isolated from F508del-CFTR mice at a concentration of 20 μM.
Brand:CaymanSKU:23481 - 50 mgAvailable on backorder
Because selective activation of peripheral cannabinoid (CB2) receptors in rat C-6 glioma cells has been shown to induce apoptosis through enhanced ceramide synthesis de novo, CB2 agonists present potential as anti glioma agents.{19828} KM 233 is a Δ8-tetrahydrocannabinol analog with a dimethyl substitution that exhibits high binding affinity for both the CB1 and CB2 receptors with 13-fold selectivity for the CB2 receptor (Kis = 12.3 and 0.91 nM, respectively).{19834} Demonstrating good lipophilicity and ability to penetrate the blood brain barrier, KM 233 inhibits human U87 glioma cell proliferation in vitro with an IC50 value of 1.4 μM and significantly reduces U87 glioma tumor size in vivo at a dose of 2 mg/kg in a SCID mouse xenograft side-pocket model.{19835}
Brand:CaymanSKU:10640 - 1 mgAvailable on backorder
Because selective activation of peripheral cannabinoid (CB2) receptors in rat C-6 glioma cells has been shown to induce apoptosis through enhanced ceramide synthesis de novo, CB2 agonists present potential as anti glioma agents.{19828} KM 233 is a Δ8-tetrahydrocannabinol analog with a dimethyl substitution that exhibits high binding affinity for both the CB1 and CB2 receptors with 13-fold selectivity for the CB2 receptor (Kis = 12.3 and 0.91 nM, respectively).{19834} Demonstrating good lipophilicity and ability to penetrate the blood brain barrier, KM 233 inhibits human U87 glioma cell proliferation in vitro with an IC50 value of 1.4 μM and significantly reduces U87 glioma tumor size in vivo at a dose of 2 mg/kg in a SCID mouse xenograft side-pocket model.{19835}
Brand:CaymanSKU:10640 - 10 mgAvailable on backorder
Because selective activation of peripheral cannabinoid (CB2) receptors in rat C-6 glioma cells has been shown to induce apoptosis through enhanced ceramide synthesis de novo, CB2 agonists present potential as anti glioma agents.{19828} KM 233 is a Δ8-tetrahydrocannabinol analog with a dimethyl substitution that exhibits high binding affinity for both the CB1 and CB2 receptors with 13-fold selectivity for the CB2 receptor (Kis = 12.3 and 0.91 nM, respectively).{19834} Demonstrating good lipophilicity and ability to penetrate the blood brain barrier, KM 233 inhibits human U87 glioma cell proliferation in vitro with an IC50 value of 1.4 μM and significantly reduces U87 glioma tumor size in vivo at a dose of 2 mg/kg in a SCID mouse xenograft side-pocket model.{19835}
Brand:CaymanSKU:10640 - 25 mgAvailable on backorder
Because selective activation of peripheral cannabinoid (CB2) receptors in rat C-6 glioma cells has been shown to induce apoptosis through enhanced ceramide synthesis de novo, CB2 agonists present potential as anti glioma agents.{19828} KM 233 is a Δ8-tetrahydrocannabinol analog with a dimethyl substitution that exhibits high binding affinity for both the CB1 and CB2 receptors with 13-fold selectivity for the CB2 receptor (Kis = 12.3 and 0.91 nM, respectively).{19834} Demonstrating good lipophilicity and ability to penetrate the blood brain barrier, KM 233 inhibits human U87 glioma cell proliferation in vitro with an IC50 value of 1.4 μM and significantly reduces U87 glioma tumor size in vivo at a dose of 2 mg/kg in a SCID mouse xenograft side-pocket model.{19835}
Brand:CaymanSKU:10640 - 5 mgAvailable on backorder
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid receptors. Monoacylglycerol lipase (MAGL) is a serine hydrolase responsible for the hydrolysis of 2-AG to arachidonic acid and glycerol, thus terminating its biological function. KML29 is an O-hexafluoroisopropyl carbamate analog of JZL 184 (Item No. 13158) that potently and selectively inhibits MAGL (IC50s = 15, 43, and 5.9 nM in mouse, rat, and human brain proteomes, respectively) over FAAH (IC50s >50 μM).{20923} At 5-20 mg/kg, KML29 dose-dependently blocks mouse brain MAGL activity in vivo, without any measurable effect on FAAH activity.{20923} As a second generation MAGL inhibitor, KML29 supersedes the low-level cross reactivity that JZL 184 displays for FAAH yet still maintains comparable potency to its parent compound.
Brand:CaymanSKU:11777 - 10 mgAvailable on backorder
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid receptors. Monoacylglycerol lipase (MAGL) is a serine hydrolase responsible for the hydrolysis of 2-AG to arachidonic acid and glycerol, thus terminating its biological function. KML29 is an O-hexafluoroisopropyl carbamate analog of JZL 184 (Item No. 13158) that potently and selectively inhibits MAGL (IC50s = 15, 43, and 5.9 nM in mouse, rat, and human brain proteomes, respectively) over FAAH (IC50s >50 μM).{20923} At 5-20 mg/kg, KML29 dose-dependently blocks mouse brain MAGL activity in vivo, without any measurable effect on FAAH activity.{20923} As a second generation MAGL inhibitor, KML29 supersedes the low-level cross reactivity that JZL 184 displays for FAAH yet still maintains comparable potency to its parent compound.
Brand:CaymanSKU:11777 - 100 mgAvailable on backorder
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid receptors. Monoacylglycerol lipase (MAGL) is a serine hydrolase responsible for the hydrolysis of 2-AG to arachidonic acid and glycerol, thus terminating its biological function. KML29 is an O-hexafluoroisopropyl carbamate analog of JZL 184 (Item No. 13158) that potently and selectively inhibits MAGL (IC50s = 15, 43, and 5.9 nM in mouse, rat, and human brain proteomes, respectively) over FAAH (IC50s >50 μM).{20923} At 5-20 mg/kg, KML29 dose-dependently blocks mouse brain MAGL activity in vivo, without any measurable effect on FAAH activity.{20923} As a second generation MAGL inhibitor, KML29 supersedes the low-level cross reactivity that JZL 184 displays for FAAH yet still maintains comparable potency to its parent compound.
Brand:CaymanSKU:11777 - 5 mgAvailable on backorder
Endocannabinoids such as 2-arachidonoyl glycerol (2-AG) and arachidonoyl ethanolamide are biologically active lipids that are involved in a number of synaptic processes including activation of cannabinoid receptors. Monoacylglycerol lipase (MAGL) is a serine hydrolase responsible for the hydrolysis of 2-AG to arachidonic acid and glycerol, thus terminating its biological function. KML29 is an O-hexafluoroisopropyl carbamate analog of JZL 184 (Item No. 13158) that potently and selectively inhibits MAGL (IC50s = 15, 43, and 5.9 nM in mouse, rat, and human brain proteomes, respectively) over FAAH (IC50s >50 μM).{20923} At 5-20 mg/kg, KML29 dose-dependently blocks mouse brain MAGL activity in vivo, without any measurable effect on FAAH activity.{20923} As a second generation MAGL inhibitor, KML29 supersedes the low-level cross reactivity that JZL 184 displays for FAAH yet still maintains comparable potency to its parent compound.
Brand:CaymanSKU:11777 - 50 mgAvailable on backorder
The prostaglandin E receptor 4 (EP4) is one of four G protein-coupled receptors that mediate the actions of prostaglandin E2 (PGE2; Item No. 14010). Binding of PGE2 to the EP4 receptor causes an increase in intracellular cyclic AMP, which plays important roles in bone formation and resorption, cancer, and atherosclerosis.{16772,16773,16619,24126} KMN-80 is a substituted γ-lactam (pyrrolidinone) derivative of PGE1 (Item No. 13010) that acts as a selective and potent agonist of EP4 with an IC50 value of 3 nM (IC50 = 1.4 μM for EP3 and > 10 μM for all other prostanoid receptors).{25026} In functional assays it has been shown to stimulate secreted alkaline phosphatase gene reporter activity in EP4-transfected HEK293 cells with an EC50 value of 0.19 nM, demonstrating >5,000 and 50,000-fold selectivity against EP2 and TP, respectively.{25026} KMN-80 can induce the differentiation of bone marrow stem cells from both young and aged rats into osteoblasts in vitro (EC50s = 20 and 153 nM, respectively) and exhibits favorable tolerability up to at least 10 μM, whereas the EP4 agonist L-902,688 (Item No. 10007712) is highly cytotoxic at similar concentrations in these cells.{25027} KMN-80 has been used to repair calvarial defects in an in vivo rat craniomaxillofacial reconstruction model (rate of reduction in defect size equivalent to BMP-2 treated rats) and to promote bone formation in a rat incisor tooth socket model.{25027}
Brand:CaymanSKU:- The prostaglandin E receptor 4 (EP4) is one of four G protein-coupled receptors that mediate the actions of prostaglandin E2 (PGE2; Item No. 14010). Binding of PGE2 to the EP4 receptor causes an increase in intracellular cyclic AMP, which plays important roles in bone formation and resorption, cancer, and atherosclerosis.{16772,16773,16619,24126} KMN-80 is a substituted γ-lactam (pyrrolidinone) derivative of PGE1 (Item No. 13010) that acts as a selective and potent agonist of EP4 with an IC50 value of 3 nM (IC50 = 1.4 μM for EP3 and > 10 μM for all other prostanoid receptors).{25026} In functional assays it has been shown to stimulate secreted alkaline phosphatase gene reporter activity in EP4-transfected HEK293 cells with an EC50 value of 0.19 nM, demonstrating >5,000 and 50,000-fold selectivity against EP2 and TP, respectively.{25026} KMN-80 can induce the differentiation of bone marrow stem cells from both young and aged rats into osteoblasts in vitro (EC50s = 20 and 153 nM, respectively) and exhibits favorable tolerability up to at least 10 μM, whereas the EP4 agonist L-902,688 (Item No. 10007712) is highly cytotoxic at similar concentrations in these cells.{25027} KMN-80 has been used to repair calvarial defects in an in vivo rat craniomaxillofacial reconstruction model (rate of reduction in defect size equivalent to BMP-2 treated rats) and to promote bone formation in a rat incisor tooth socket model.{25027}
Brand:CaymanSKU:- The prostaglandin E receptor 4 (EP4) is one of four G protein-coupled receptors that mediate the actions of prostaglandin E2 (PGE2; Item No. 14010). Binding of PGE2 to the EP4 receptor causes an increase in intracellular cyclic AMP, which plays important roles in bone formation and resorption, cancer, and atherosclerosis.{16772,16773,16619,24126} KMN-80 is a substituted γ-lactam (pyrrolidinone) derivative of PGE1 (Item No. 13010) that acts as a selective and potent agonist of EP4 with an IC50 value of 3 nM (IC50 = 1.4 μM for EP3 and > 10 μM for all other prostanoid receptors).{25026} In functional assays it has been shown to stimulate secreted alkaline phosphatase gene reporter activity in EP4-transfected HEK293 cells with an EC50 value of 0.19 nM, demonstrating >5,000 and 50,000-fold selectivity against EP2 and TP, respectively.{25026} KMN-80 can induce the differentiation of bone marrow stem cells from both young and aged rats into osteoblasts in vitro (EC50s = 20 and 153 nM, respectively) and exhibits favorable tolerability up to at least 10 μM, whereas the EP4 agonist L-902,688 (Item No. 10007712) is highly cytotoxic at similar concentrations in these cells.{25027} KMN-80 has been used to repair calvarial defects in an in vivo rat craniomaxillofacial reconstruction model (rate of reduction in defect size equivalent to BMP-2 treated rats) and to promote bone formation in a rat incisor tooth socket model.{25027}
Brand:CaymanSKU:-
KN-62 is a selective, cell permeable inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII; IC50 = 900 nM).{17252} It does not affect the activity of several other kinases when tested at 10 µM.{12847} KN-62 also acts as a non-competitive antagonist of the purinergic receptor P2RX7 (IC50 = 15 nM).{17253}
Brand:CaymanSKU:- KN-62 is a selective, cell permeable inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII; IC50 = 900 nM).{17252} It does not affect the activity of several other kinases when tested at 10 µM.{12847} KN-62 also acts as a non-competitive antagonist of the purinergic receptor P2RX7 (IC50 = 15 nM).{17253}
Brand:CaymanSKU:- KN-62 is a selective, cell permeable inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII; IC50 = 900 nM).{17252} It does not affect the activity of several other kinases when tested at 10 µM.{12847} KN-62 also acts as a non-competitive antagonist of the purinergic receptor P2RX7 (IC50 = 15 nM).{17253}
Brand:CaymanSKU:- KN-62 is a selective, cell permeable inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII; IC50 = 900 nM).{17252} It does not affect the activity of several other kinases when tested at 10 µM.{12847} KN-62 also acts as a non-competitive antagonist of the purinergic receptor P2RX7 (IC50 = 15 nM).{17253}
Brand:CaymanSKU:-
KN-92 is an inactive derivative of KN-93, the selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII).{17325} At concentrations up to 25 μM, KN-92 is ineffective at inhibiting CaMKII or arresting cell growth of NIH 3T3 fibroblasts.{19487} It is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93 (Item No. 13319).
Brand:CaymanSKU:9000890 - 1 mgAvailable on backorder
KN-92 is an inactive derivative of KN-93, the selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII).{17325} At concentrations up to 25 μM, KN-92 is ineffective at inhibiting CaMKII or arresting cell growth of NIH 3T3 fibroblasts.{19487} It is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93 (Item No. 13319).
Brand:CaymanSKU:9000890 - 10 mgAvailable on backorder
KN-92 is an inactive derivative of KN-93, the selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII).{17325} At concentrations up to 25 μM, KN-92 is ineffective at inhibiting CaMKII or arresting cell growth of NIH 3T3 fibroblasts.{19487} It is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93 (Item No. 13319).
Brand:CaymanSKU:9000890 - 5 mgAvailable on backorder
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).{17325} It does not affect the activities of PKA, PKC, MLCK, or Ca2+-phosphodiesterase.{17325} It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:- KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).{17325} It does not affect the activities of PKA, PKC, MLCK, or Ca2+-phosphodiesterase.{17325} It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:- KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).{17325} It does not affect the activities of PKA, PKC, MLCK, or Ca2+-phosphodiesterase.{17325} It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:-
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).{17325} It does not affect the activities of PKA, PKC, MLCK, or Ca2+-phosphodiesterase.{17325} It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:- KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).{17325} It does not affect the activities of PKA, PKC, MLCK, or Ca2+-phosphodiesterase.{17325} It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:- KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase type II (CaMKII), competitively blocking CaM binding to the kinase (Ki = 370 nM).{17325} It does not affect the activities of PKA, PKC, MLCK, or Ca2+-phosphodiesterase.{17325} It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:-
KN-93 (phosphate) is a potent and selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII) (Ki = 370 nM), inhibiting both the α- and β-subunits of CaMKII.{17325} It does not have significant effects on cAMP-dependent protein kinase, Ca2+/phospholipid-dependent protein kinase, myosin light chain kinase, or Ca2+ phosphodiesterase activity. It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} KN-93 can block voltage-gated potassium (Kv) channels when applied extracellularly, independent of its CaMKII action.{33674} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:21472 -Out of stock
KN-93 (phosphate) is a potent and selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII) (Ki = 370 nM), inhibiting both the α- and β-subunits of CaMKII.{17325} It does not have significant effects on cAMP-dependent protein kinase, Ca2+/phospholipid-dependent protein kinase, myosin light chain kinase, or Ca2+ phosphodiesterase activity. It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} KN-93 can block voltage-gated potassium (Kv) channels when applied extracellularly, independent of its CaMKII action.{33674} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:21472 -Out of stock
KN-93 (phosphate) is a potent and selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII) (Ki = 370 nM), inhibiting both the α- and β-subunits of CaMKII.{17325} It does not have significant effects on cAMP-dependent protein kinase, Ca2+/phospholipid-dependent protein kinase, myosin light chain kinase, or Ca2+ phosphodiesterase activity. It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} KN-93 can block voltage-gated potassium (Kv) channels when applied extracellularly, independent of its CaMKII action.{33674} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:21472 -Out of stock
KN-93 (phosphate) is a potent and selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII) (Ki = 370 nM), inhibiting both the α- and β-subunits of CaMKII.{17325} It does not have significant effects on cAMP-dependent protein kinase, Ca2+/phospholipid-dependent protein kinase, myosin light chain kinase, or Ca2+ phosphodiesterase activity. It inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM).{17326} KN-93 can block voltage-gated potassium (Kv) channels when applied extracellularly, independent of its CaMKII action.{33674} More recently, KN-93 has been used to implicate roles for CaMKII in Ca2+-induced Ca2+ release in cardiac myocytes, constitutive phosphorylation of 5-lipoxygenase in 3T3 cells, and Ca2+-dependent activation of HIF-1α in colon cancer cells.{17327,17328,17329}
Brand:CaymanSKU:21472 -Out of stock
Breast cancer resistance protein (BCRP) is an ATP-binding cassette protein known also as ABCG2. While it normally functions as a high-capacity urate exporter in the renal system, it also acts as a xenobiotic transporter and contributes to multidrug resistance (e.g., to mitoxantrone) in certain types of cancer.{24807} BCRP is abundant at the intestinal epithelium and blood-brain barrier, potentially restricting the distribution of certain drugs.{24809,24808} Ko 143 is a potent and selective inhibitor of BCRP, preventing the export of mitoxantrone and topotecan in breast cancer cell lines (EC50s = 23 and 26 nM, respectively).{24809} It is much less effective at the transporters P-glycoprotein and multidrug resistance-associated protein 1, MRP1.{24809} Ko 143 is effective in vivo in mice.{24809,24808}
Brand:CaymanSKU:- Breast cancer resistance protein (BCRP) is an ATP-binding cassette protein known also as ABCG2. While it normally functions as a high-capacity urate exporter in the renal system, it also acts as a xenobiotic transporter and contributes to multidrug resistance (e.g., to mitoxantrone) in certain types of cancer.{24807} BCRP is abundant at the intestinal epithelium and blood-brain barrier, potentially restricting the distribution of certain drugs.{24809,24808} Ko 143 is a potent and selective inhibitor of BCRP, preventing the export of mitoxantrone and topotecan in breast cancer cell lines (EC50s = 23 and 26 nM, respectively).{24809} It is much less effective at the transporters P-glycoprotein and multidrug resistance-associated protein 1, MRP1.{24809} Ko 143 is effective in vivo in mice.{24809,24808}
Brand:CaymanSKU:- Breast cancer resistance protein (BCRP) is an ATP-binding cassette protein known also as ABCG2. While it normally functions as a high-capacity urate exporter in the renal system, it also acts as a xenobiotic transporter and contributes to multidrug resistance (e.g., to mitoxantrone) in certain types of cancer.{24807} BCRP is abundant at the intestinal epithelium and blood-brain barrier, potentially restricting the distribution of certain drugs.{24809,24808} Ko 143 is a potent and selective inhibitor of BCRP, preventing the export of mitoxantrone and topotecan in breast cancer cell lines (EC50s = 23 and 26 nM, respectively).{24809} It is much less effective at the transporters P-glycoprotein and multidrug resistance-associated protein 1, MRP1.{24809} Ko 143 is effective in vivo in mice.{24809,24808}
Brand:CaymanSKU:- Breast cancer resistance protein (BCRP) is an ATP-binding cassette protein known also as ABCG2. While it normally functions as a high-capacity urate exporter in the renal system, it also acts as a xenobiotic transporter and contributes to multidrug resistance (e.g., to mitoxantrone) in certain types of cancer.{24807} BCRP is abundant at the intestinal epithelium and blood-brain barrier, potentially restricting the distribution of certain drugs.{24809,24808} Ko 143 is a potent and selective inhibitor of BCRP, preventing the export of mitoxantrone and topotecan in breast cancer cell lines (EC50s = 23 and 26 nM, respectively).{24809} It is much less effective at the transporters P-glycoprotein and multidrug resistance-associated protein 1, MRP1.{24809} Ko 143 is effective in vivo in mice.{24809,24808}
Brand:CaymanSKU:-
KO947 is an ERK inhibitor (IC50 = V600E with an IC50 value of less than 250 nM.{46896} It inhibits proliferation of A375 cells, as well as mutant K-Ras-expressing HCT116 and H358 cancer cell lines (IC50s = 50-250 nM for all).
Brand:CaymanSKU:29213 - 1 mgAvailable on backorder
KO947 is an ERK inhibitor (IC50 = V600E with an IC50 value of less than 250 nM.{46896} It inhibits proliferation of A375 cells, as well as mutant K-Ras-expressing HCT116 and H358 cancer cell lines (IC50s = 50-250 nM for all).
Brand:CaymanSKU:29213 - 10 mgAvailable on backorder
KO947 is an ERK inhibitor (IC50 = V600E with an IC50 value of less than 250 nM.{46896} It inhibits proliferation of A375 cells, as well as mutant K-Ras-expressing HCT116 and H358 cancer cell lines (IC50s = 50-250 nM for all).
Brand:CaymanSKU:29213 - 25 mgAvailable on backorder
KO947 is an ERK inhibitor (IC50 = V600E with an IC50 value of less than 250 nM.{46896} It inhibits proliferation of A375 cells, as well as mutant K-Ras-expressing HCT116 and H358 cancer cell lines (IC50s = 50-250 nM for all).
Brand:CaymanSKU:29213 - 5 mgAvailable on backorder
The Ras family of small GTPases (H-Ras, K-Ras, and N-Ras) function as molecular switches, cycling between a GTP-bound active state and a GDP-bound inactive state, to turn on downstream Raf protein kinases. This initiates complex signaling pathways involved in cell growth, differentiation, and apoptosis. Mutations leading to aberrant Ras activation are frequently associated with various human cancers. Kobe 0065 is an orally active Ras inhibitor with selectivity for H-Ras (Ki = 46 μM).{27843} It can inhibit both anchorage-dependent and -independent growth and induce apoptosis of H-RasG12V-transformed NIH 3T3 cells (IC50 = ~1.5 μM), which leads to a down-regulation of MEK/ERK, Akt, RalA, and Son of sevenless.{27843} At an oral dose of 80 mg/kg, Kobe 0065 also exhibits antitumor activity in mice bearing a xenograft of human colon cancer SW480 cells expressing K-RasG12V.{27843}
Brand:CaymanSKU:- The Ras family of small GTPases (H-Ras, K-Ras, and N-Ras) function as molecular switches, cycling between a GTP-bound active state and a GDP-bound inactive state, to turn on downstream Raf protein kinases. This initiates complex signaling pathways involved in cell growth, differentiation, and apoptosis. Mutations leading to aberrant Ras activation are frequently associated with various human cancers. Kobe 0065 is an orally active Ras inhibitor with selectivity for H-Ras (Ki = 46 μM).{27843} It can inhibit both anchorage-dependent and -independent growth and induce apoptosis of H-RasG12V-transformed NIH 3T3 cells (IC50 = ~1.5 μM), which leads to a down-regulation of MEK/ERK, Akt, RalA, and Son of sevenless.{27843} At an oral dose of 80 mg/kg, Kobe 0065 also exhibits antitumor activity in mice bearing a xenograft of human colon cancer SW480 cells expressing K-RasG12V.{27843}
Brand:CaymanSKU:- The Ras family of small GTPases (H-Ras, K-Ras, and N-Ras) function as molecular switches, cycling between a GTP-bound active state and a GDP-bound inactive state, to turn on downstream Raf protein kinases. This initiates complex signaling pathways involved in cell growth, differentiation, and apoptosis. Mutations leading to aberrant Ras activation are frequently associated with various human cancers. Kobe 0065 is an orally active Ras inhibitor with selectivity for H-Ras (Ki = 46 μM).{27843} It can inhibit both anchorage-dependent and -independent growth and induce apoptosis of H-RasG12V-transformed NIH 3T3 cells (IC50 = ~1.5 μM), which leads to a down-regulation of MEK/ERK, Akt, RalA, and Son of sevenless.{27843} At an oral dose of 80 mg/kg, Kobe 0065 also exhibits antitumor activity in mice bearing a xenograft of human colon cancer SW480 cells expressing K-RasG12V.{27843}
Brand:CaymanSKU:- The Ras family of small GTPases (H-Ras, K-Ras, and N-Ras) function as molecular switches, cycling between a GTP-bound active state and a GDP-bound inactive state, to turn on downstream Raf protein kinases. This initiates complex signaling pathways involved in cell growth, differentiation, and apoptosis. Mutations leading to aberrant Ras activation are frequently associated with various human cancers. Kobe 0065 is an orally active Ras inhibitor with selectivity for H-Ras (Ki = 46 μM).{27843} It can inhibit both anchorage-dependent and -independent growth and induce apoptosis of H-RasG12V-transformed NIH 3T3 cells (IC50 = ~1.5 μM), which leads to a down-regulation of MEK/ERK, Akt, RalA, and Son of sevenless.{27843} At an oral dose of 80 mg/kg, Kobe 0065 also exhibits antitumor activity in mice bearing a xenograft of human colon cancer SW480 cells expressing K-RasG12V.{27843}
Brand:CaymanSKU:-
The Ras family of small GTPases (H-Ras, K-Ras, and N-Ras) function as molecular switches, cycling between a GTP-bound active state and a GDP-bound inactive state, to turn on downstream Raf protein kinases. This initiates complex signaling pathways involved in cell growth, differentiation, and apoptosis. Mutations leading to aberrant Ras activation are frequently associated with various human cancers. Kobe 2602 is a selective Ras inhibitor that blocks H-Ras GTP binding to c-Raf-1 (Ki = 149 µM).{27843} Kobe 2602 has been shown to inhibit both anchorage-dependent and -independent growth and to induce apoptosis of H-RasG12V-transformed NIH 3T3 cells (IC50 = 1.4-2 µM).{27843} At an oral dose of 80 mg/kg, it also exhibits antitumor activity in mice bearing a xenograft of human colon cancer SW480 cells expressing K-RasG12V.{27843}
Brand:CaymanSKU:- The Ras family of small GTPases (H-Ras, K-Ras, and N-Ras) function as molecular switches, cycling between a GTP-bound active state and a GDP-bound inactive state, to turn on downstream Raf protein kinases. This initiates complex signaling pathways involved in cell growth, differentiation, and apoptosis. Mutations leading to aberrant Ras activation are frequently associated with various human cancers. Kobe 2602 is a selective Ras inhibitor that blocks H-Ras GTP binding to c-Raf-1 (Ki = 149 µM).{27843} Kobe 2602 has been shown to inhibit both anchorage-dependent and -independent growth and to induce apoptosis of H-RasG12V-transformed NIH 3T3 cells (IC50 = 1.4-2 µM).{27843} At an oral dose of 80 mg/kg, it also exhibits antitumor activity in mice bearing a xenograft of human colon cancer SW480 cells expressing K-RasG12V.{27843}
Brand:CaymanSKU:- The Ras family of small GTPases (H-Ras, K-Ras, and N-Ras) function as molecular switches, cycling between a GTP-bound active state and a GDP-bound inactive state, to turn on downstream Raf protein kinases. This initiates complex signaling pathways involved in cell growth, differentiation, and apoptosis. Mutations leading to aberrant Ras activation are frequently associated with various human cancers. Kobe 2602 is a selective Ras inhibitor that blocks H-Ras GTP binding to c-Raf-1 (Ki = 149 µM).{27843} Kobe 2602 has been shown to inhibit both anchorage-dependent and -independent growth and to induce apoptosis of H-RasG12V-transformed NIH 3T3 cells (IC50 = 1.4-2 µM).{27843} At an oral dose of 80 mg/kg, it also exhibits antitumor activity in mice bearing a xenograft of human colon cancer SW480 cells expressing K-RasG12V.{27843}
Brand:CaymanSKU:- The Ras family of small GTPases (H-Ras, K-Ras, and N-Ras) function as molecular switches, cycling between a GTP-bound active state and a GDP-bound inactive state, to turn on downstream Raf protein kinases. This initiates complex signaling pathways involved in cell growth, differentiation, and apoptosis. Mutations leading to aberrant Ras activation are frequently associated with various human cancers. Kobe 2602 is a selective Ras inhibitor that blocks H-Ras GTP binding to c-Raf-1 (Ki = 149 µM).{27843} Kobe 2602 has been shown to inhibit both anchorage-dependent and -independent growth and to induce apoptosis of H-RasG12V-transformed NIH 3T3 cells (IC50 = 1.4-2 µM).{27843} At an oral dose of 80 mg/kg, it also exhibits antitumor activity in mice bearing a xenograft of human colon cancer SW480 cells expressing K-RasG12V.{27843}
Brand:CaymanSKU:-
Kocurin is a thiazolyl peptide originally isolated from K. palustris and has antibiotic activity.{52349} It is active against methicillin-resistant S. aureus (MRSA; MIC = 0.25 µg/ml), as well as B. subtilis and E. faecium in a solid agar test when used at a concentration of 8 µg/ml. Kocurin is also active against E. faecium, E. faecalis, S. epidermidis, and clinical isolates of vancomycin-resistant enterococci (MICs = 0.004-1.025 µg/ml).{52350} In vivo, kocurin (2.5, 5, and 10 mg/ml) increases survival in a mouse model of E. faecium-induced septicemia. It decreases the number of colony forming units (CFUs) in a mouse model of MRSA lung infection.
Brand:CaymanSKU:29125 - 1 mgAvailable on backorder
Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic.{9800} Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position.{9891} 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine, or KOdiA-PC, is one of the most potent CD36 ligands among the oxLDL species.{9890} KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle, and may be one of the more important structural determinants of oxLDL.
Brand:CaymanSKU:62945 - 1 mgAvailable on backorder
Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic.{9800} Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position.{9891} 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine, or KOdiA-PC, is one of the most potent CD36 ligands among the oxLDL species.{9890} KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle, and may be one of the more important structural determinants of oxLDL.
Brand:CaymanSKU:62945 - 10 mgAvailable on backorder
Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic.{9800} Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position.{9891} 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine, or KOdiA-PC, is one of the most potent CD36 ligands among the oxLDL species.{9890} KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle, and may be one of the more important structural determinants of oxLDL.
Brand:CaymanSKU:62945 - 5 mgAvailable on backorder
Oxidized low-density lipoprotien (oxLDL) particles contain low molecular weight species which are cytotoxic and pro-atherogenic.{9800} Many of these substances were recently isolated and purified from oxLDL, and identified as phosphatidylcholine species containing a fragmented, oxidized short-chain fatty acid remnant at the sn-2 position.{9891} 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine, or KOdiA-PC, is one of the most potent CD36 ligands among the oxLDL species.{9890} KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle, and may be one of the more important structural determinants of oxLDL.
Brand:CaymanSKU:62945 - 500 µgAvailable on backorder
Kojic acid is a fungal metabolite that inhibits tyrosinase, an enzyme involved in melanin synthesis, with an IC50 value of 30.6 µM for mushroom tyrosinase.{38117} It decreases growth of Leishmania parasites in vitro and in vivo, and it protects mice from damage induced by gamma irradiation.{38118,38119} Kojic acid has been used as a food additive to prevent enzymatic browning.{38116} Formulations containing kojic acid are used in the treatment of hyperpigmentation disorders.{21434}
Brand:CaymanSKU:22712 -Out of stock
Kojic acid is a fungal metabolite that inhibits tyrosinase, an enzyme involved in melanin synthesis, with an IC50 value of 30.6 µM for mushroom tyrosinase.{38117} It decreases growth of Leishmania parasites in vitro and in vivo, and it protects mice from damage induced by gamma irradiation.{38118,38119} Kojic acid has been used as a food additive to prevent enzymatic browning.{38116} Formulations containing kojic acid are used in the treatment of hyperpigmentation disorders.{21434}
Brand:CaymanSKU:22712 -Out of stock
Kojic acid is a fungal metabolite that inhibits tyrosinase, an enzyme involved in melanin synthesis, with an IC50 value of 30.6 µM for mushroom tyrosinase.{38117} It decreases growth of Leishmania parasites in vitro and in vivo, and it protects mice from damage induced by gamma irradiation.{38118,38119} Kojic acid has been used as a food additive to prevent enzymatic browning.{38116} Formulations containing kojic acid are used in the treatment of hyperpigmentation disorders.{21434}
Brand:CaymanSKU:22712 -Out of stock
Kojic acid is a fungal metabolite that inhibits tyrosinase, an enzyme involved in melanin synthesis, with an IC50 value of 30.6 µM for mushroom tyrosinase.{38117} It decreases growth of Leishmania parasites in vitro and in vivo, and it protects mice from damage induced by gamma irradiation.{38118,38119} Kojic acid has been used as a food additive to prevent enzymatic browning.{38116} Formulations containing kojic acid are used in the treatment of hyperpigmentation disorders.{21434}
Brand:CaymanSKU:22712 -Out of stock
Kotanin A is a fungal metabolite produced by A. glaucus (A. clavatus), A. alliaceus, and A. niger.{36638,36637} It is toxic to day-old chicks (LD100 = 62.5 mg/kg) but has no effect in rats.{36638}
Brand:CaymanSKU:24917 - 2.5 mgAvailable on backorder
Kotanin A is a fungal metabolite produced by A. glaucus (A. clavatus), A. alliaceus, and A. niger.{36638,36637} It is toxic to day-old chicks (LD100 = 62.5 mg/kg) but has no effect in rats.{36638}
Brand:CaymanSKU:24917 - 500 µgAvailable on backorder
KP372-1 is a specific Akt inhibitor that demonstrates at least 10-fold selectivity against a panel of additional kinase targets, including CDK1, ERK1, GSK3β, LCK, MEK1, PKA, PKC, and S6K.{26547,26546} By blocking Akt signaling, KP372-1 has been shown to inhibit proliferation and to induce apoptosis of thyroid cancer cells with an IC50 value of 30-60 nM in vitro.{26546} In acute myelogenous leukemia cells, KP372-1 is reported to inhibit the kinase activity of Akt, PDK1, and FLT3, decreasing the colony-forming ability of these cells with an IC50 value less than 200 nM.{26547}
Brand:CaymanSKU:-Available on backorder
KP372-1 is a specific Akt inhibitor that demonstrates at least 10-fold selectivity against a panel of additional kinase targets, including CDK1, ERK1, GSK3β, LCK, MEK1, PKA, PKC, and S6K.{26547,26546} By blocking Akt signaling, KP372-1 has been shown to inhibit proliferation and to induce apoptosis of thyroid cancer cells with an IC50 value of 30-60 nM in vitro.{26546} In acute myelogenous leukemia cells, KP372-1 is reported to inhibit the kinase activity of Akt, PDK1, and FLT3, decreasing the colony-forming ability of these cells with an IC50 value less than 200 nM.{26547}
Brand:CaymanSKU:-Available on backorder
KP372-1 is a specific Akt inhibitor that demonstrates at least 10-fold selectivity against a panel of additional kinase targets, including CDK1, ERK1, GSK3β, LCK, MEK1, PKA, PKC, and S6K.{26547,26546} By blocking Akt signaling, KP372-1 has been shown to inhibit proliferation and to induce apoptosis of thyroid cancer cells with an IC50 value of 30-60 nM in vitro.{26546} In acute myelogenous leukemia cells, KP372-1 is reported to inhibit the kinase activity of Akt, PDK1, and FLT3, decreasing the colony-forming ability of these cells with an IC50 value less than 200 nM.{26547}
Brand:CaymanSKU:-Available on backorder
KPT-185 is an inhibitor of Exportin 1 (XPO1/CRM1) with anticancer activity.{47263,31566} It reduces proliferation in a panel of patient-derived acute myeloid leukemia cells (IC50s = 100-500 nM).{47263} KPT-185 induces cell cycle arrest in the G1 phase and apoptosis in MOLT-4 T cell acute lymphoblastic leukemia cells and in a panel of six non-small cell lung cancer (NSCLC) cell lines in a time- and dose-dependent manner.{31566,47264}
Brand:CaymanSKU:26074 - 10 mgAvailable on backorder
KPT-185 is an inhibitor of Exportin 1 (XPO1/CRM1) with anticancer activity.{47263,31566} It reduces proliferation in a panel of patient-derived acute myeloid leukemia cells (IC50s = 100-500 nM).{47263} KPT-185 induces cell cycle arrest in the G1 phase and apoptosis in MOLT-4 T cell acute lymphoblastic leukemia cells and in a panel of six non-small cell lung cancer (NSCLC) cell lines in a time- and dose-dependent manner.{31566,47264}
Brand:CaymanSKU:26074 - 25 mgAvailable on backorder
KPT-185 is an inhibitor of Exportin 1 (XPO1/CRM1) with anticancer activity.{47263,31566} It reduces proliferation in a panel of patient-derived acute myeloid leukemia cells (IC50s = 100-500 nM).{47263} KPT-185 induces cell cycle arrest in the G1 phase and apoptosis in MOLT-4 T cell acute lymphoblastic leukemia cells and in a panel of six non-small cell lung cancer (NSCLC) cell lines in a time- and dose-dependent manner.{31566,47264}
Brand:CaymanSKU:26074 - 5 mgAvailable on backorder
KPT-276 is an orally bioavailable inhibitor of Exportin 1 (XPO1/CRM1) with anticancer activity.{47263} In vivo, KPT-276 (150 mg/kg) increases survival and reduces spleen weight and white blood cell count in an MV4-11 acute myeloid leukemia (AML) mouse xenograft model. It also reduces tumor volume and increases survival in a BT 145 glioblastoma mouse xenograft model when administered at a dose of 75 mg/kg.{53291}
Brand:CaymanSKU:29158 - 10 mgAvailable on backorder
KPT-276 is an orally bioavailable inhibitor of Exportin 1 (XPO1/CRM1) with anticancer activity.{47263} In vivo, KPT-276 (150 mg/kg) increases survival and reduces spleen weight and white blood cell count in an MV4-11 acute myeloid leukemia (AML) mouse xenograft model. It also reduces tumor volume and increases survival in a BT 145 glioblastoma mouse xenograft model when administered at a dose of 75 mg/kg.{53291}
Brand:CaymanSKU:29158 - 25 mgAvailable on backorder
KPT-276 is an orally bioavailable inhibitor of Exportin 1 (XPO1/CRM1) with anticancer activity.{47263} In vivo, KPT-276 (150 mg/kg) increases survival and reduces spleen weight and white blood cell count in an MV4-11 acute myeloid leukemia (AML) mouse xenograft model. It also reduces tumor volume and increases survival in a BT 145 glioblastoma mouse xenograft model when administered at a dose of 75 mg/kg.{53291}
Brand:CaymanSKU:29158 - 5 mgAvailable on backorder